Trump on Wednesday called Overton, a longtime ally and current White House domestic policy adviser, a “ROCKSTAR” who “is known to take on the HARDEST issues and bring me solutions that work best for the Country.” Health and Human Services Secretary Robert F. Kennedy Jr., the effective leader of the MAHA movement, praised Overton on X following her nomination, but she is not the first choice among MAHA activists, many of whom see her as too embedded in the traditional public health establishment.
Overton earned her medical degree in 2013 through a joint BA/MD program at the University of New Mexico that provided a comprehensive medical ethics education. She did her postgraduation training at Johns Hopkins University, where she earned a Ph.D. in clinical investigations.While at Johns Hopkins, Overton worked with Trump’s first FDA commissioner, Dr. Marty Makary, on various projects, including several peer-reviewed papers and articles regarding overprescribing opioids and other pharmaceuticals. But some MAHA advocates have already begun to chafe at the idea of her being atop the massive regulatory agency that oversees a variety of their policy priorities, particularly changes to the childhood vaccine schedule, pesticide policy, and peptides.When asked about conflicts between Overton and ardent MAHA supporters, White House spokesman Kush Desai told the Washington Examiner that Overton “has played an integral role in nearly every single MAHA policy victory by the Trump administration.” “No one has worked harder to ensure that these historic policy changes are legally durable, medically correct, and grounded in Gold Standard Science than Dr. Overton,” Desai said.Here are some of the key issues that are likely to strain her relationship with MAHA advocates should she be confirmed by the Senate.
